文献速递前列腺癌

SelectMDx尿液生物标志物检测联合或不联合mpMRI在前列腺癌诊断中的临床应用:一项针对未活检男性的前瞻性多中心研究

Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-03

这项前瞻性多中心诊断研究纳入599例PSA≥3 ng/ml的未活检男性,评估SelectMDx检测高级别前列腺癌及联合mpMRI对活检选择的影响。结果显示SelectMDx可避免38%活检,漏诊10%高级别癌;mpMRI全用净获益最高,避免49%活检,漏诊4.9%高级别癌。

要点

  • SelectMDx可避免38%不必要的活检,漏诊10%高级别前列腺癌。
  • mpMRI全用策略净获益最高,避免49%活检,漏诊4.9%高级别癌。
  • mpMRI资源有限时,对SelectMDx阳性者行mpMRI是良好替代策略。

核心结论

  • SelectMDx作为未活检男性的风险分层工具可避免38%不必要的活检,减少低级别前列腺癌检出,仅漏诊10%高级别前列腺癌。
  • 全用mpMRI净获益最高,避免49%活检,漏诊4.9%高级别前列腺癌;若mpMRI有限或昂贵,对SelectMDx阳性者行mpMRI是良好替代策略。

研究设计与样本

  • 前瞻性多中心诊断研究,纳入599例PSA≥3 ng/ml的未活检男性。
  • 所有患者行SelectMDx检测和mpMRI,随后行系统经直肠超声引导活检(TRUSGB);mpMRI可疑者加行MR引导活检(MRGB)。
  • 以TRUSGB和MRGB的组织病理学结果为参考标准,高级别前列腺癌定义为ISUP分级分组(GG)≥2。

主要发现

  • 高级别前列腺癌患病率为31%(183/599)。
  • 38%(227/599)患者SelectMDx阴性可避免活检,低级别前列腺癌漏诊35%(48/138),高级别前列腺癌漏诊10%(18/183)。
  • 仅mpMRI策略可避免49%活检,漏诊4.9%(9/183)高级别前列腺癌。
  • 条件策略减少38%(227/599)mpMRI,避免60%(357/599)活检,漏诊13%(24/183)高级别前列腺癌,低级别前列腺癌漏诊58%(80/138)。
  • 决策曲线分析显示,在风险阈值>10%时,仅mpMRI策略净获益最高,条件策略次之。

关键数值与推荐

  • SelectMDx阳性定义为风险评分≥-2.8。
  • 高级别前列腺癌定义为ISUP分级分组(GG)≥2。

临床怎么用

  • SelectMDx可用于未活检男性的风险分层,避免38%不必要的活检,减少低级别前列腺癌检出。
  • 若mpMRI资源充足,全用mpMRI净获益最高,可避免49%活检,漏诊4.9%高级别前列腺癌。
  • 若mpMRI有限或昂贵,对SelectMDx阳性者行mpMRI是良好替代策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk stratification in men with suspicion of prostate cancer (PCa) requires reliable diagnostic tests, not only to identify high-grade PCa, also to minimize the overdetection of low-grade PCa, and reduction of "unnecessary" prostate MRIs and biopsies. This study aimed to evaluate the SelectMDx test to detect high-grade PCa in biopsy-naïve men. Subsequently, to assess combinations of SelectMDx test and multi-parametric (mp) MRI and its potential impact on patient selection for prostate biopsy. METHODS: This prospective multicenter diagnostic study included 599 biopsy-naïve patients with prostate-specific antigen level ≥3 ng/ml. All patients underwent a SelectMDx test and mpMRI before systematic transrectal ultrasound-guided biopsy (TRUSGB). Patients with a suspicious mpMRI also had an in-bore MR-guided biopsy (MRGB). Histopathologic outcome of TRUSGB and MRGB was used as reference standard. High-grade PCa was defined as ISUP Grade Group (GG) ≥ 2. The primary outcome was the detection rates of low- and high-grade PCa and number of biopsies avoided in four strategies, i.e., (1) SelectMDx test-only, (2) mpMRI-only, (3) SelectMDx test followed by mpMRI when SelectMDx test was positive (conditional strategy), and (4) SelectMDx test and mpMRI in all (joint strategy). A positive SelectMDx test outcome was a risk score of ≥-2.8. Decision curve analysis (DCA) was performed to assess clinical utility. RESULTS: Prevalence of high-grade PCa was 31% (183/599). Thirty-eight percent (227/599) of patients had negative SelectMDx test in whom biopsy could be avoided. Low-grade PCa was not detected in 35% (48/138) with missing 10% (18/183) high-grade PCa. Yet, mpMRI-only could avoid 49% of biopsies, not detecting 4.9% (9/183) of high-grade PCa. The conditional strategy reduces the number of mpMRIs by 38% (227/599), avoiding biopsy in 60% (357/599) and missing 13% (24/183) high-grade PCa. Low-grade PCa was not detected in 58% (80/138). DCA showed the highest net benefit for the mpMRI-only strategy, followed by the conditional strategy at-risk thresholds >10%. CONCLUSIONS: SelectMDx test as a risk stratification tool for biopsy-naïve men avoids unnecessary biopsies in 38%, minimizes low-grade PCa detection, and misses only 10% high-grade PCa. Yet, using mpMRI in all patients had the highest net benefit, avoiding biopsy in 49% and missing 4.9% of high-risk PCa. However, if mpMRI availability is limited or expensive, using mpMRI-only in SelectMDx test positive patients is a good alternative strategy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Hendriks RJ, van der Leest MMG, Israël B, et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer Prostatic Dis. 2021. PMID: 33941866. doi:10.1038/s41391-021-00367-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。